Johnson & Johnson $JNJ Stake Boosted by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,336,570 shares of the company’s stock after purchasing an additional 58,143 shares during the period. Adage Capital Partners GP L.L.C. owned about 0.06% of Johnson & Johnson worth $204,161,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of JNJ. CTC Alternative Strategies Ltd. boosted its holdings in shares of Johnson & Johnson by 33.6% in the 2nd quarter. CTC Alternative Strategies Ltd. now owns 3,740 shares of the company’s stock valued at $571,000 after buying an additional 940 shares during the period. Strategic Wealth Investment Group LLC lifted its holdings in Johnson & Johnson by 2.2% in the second quarter. Strategic Wealth Investment Group LLC now owns 5,921 shares of the company’s stock worth $904,000 after acquiring an additional 126 shares during the last quarter. Vista Capital Partners Inc. boosted its stake in Johnson & Johnson by 3.9% in the second quarter. Vista Capital Partners Inc. now owns 5,373 shares of the company’s stock valued at $821,000 after acquiring an additional 202 shares during the period. Florida Financial Advisors LLC grew its holdings in shares of Johnson & Johnson by 17.6% during the second quarter. Florida Financial Advisors LLC now owns 9,255 shares of the company’s stock valued at $1,431,000 after purchasing an additional 1,387 shares during the last quarter. Finally, Nia Impact Advisors LLC raised its position in shares of Johnson & Johnson by 8.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 2,091 shares of the company’s stock worth $319,000 after purchasing an additional 159 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, Citigroup upped their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research report on Thursday. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $206.65.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $211.65 on Friday. The firm has a market capitalization of $509.93 billion, a PE ratio of 20.43, a P/E/G ratio of 2.34 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $196.09 and a 200 day moving average price of $177.08. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $212.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.